Figure 5.

The effect of twice-daily oral dosing with the MEK inhibitor PD184161 on the growth of newly inoculated Hep3B tumor xenografts in nude mice (n = 7). Mice were treated with PD184161 (300 mg/kg) beginning 12 hours after Hep3B inoculation and continued for 38 days. Tumors were measured every 3 days, and volumes are represented in the figure (▲ vehicle; ■ PD184161). Tumor measurements in PD184161-treated animals were found to be statistically significant from control at all time points shown (t-test; P < .05).